Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Published:2019-07-10 Issue:10 Volume:94 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Aldoss Ibrahim¹,Yang Dongyun²,Pillai Raju³,Sanchez James F.¹^ORCID,Mei Matthew¹,Aribi Ahmed¹,Ali Haris¹,Sandhu Karamjeet¹,Al Malki Monzr M.¹^ORCID,Salhotra Amandeep¹,Khaled Samer¹,Sun Weili⁴,O'Donnell Margaret¹,Snyder David¹,Nakamura Ryotaro¹,Stein Anthony S.¹,Forman Stephen J.³,Marcucci Guido¹,Pullarkat Vinod¹^ORCID

Affiliation:

1. Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell TransplantationCity of Hope Medical Center Duarte California

2. Department of Information SciencesCity of Hope Medical Center Duarte California

3. Department of PathologyCity of Hope Medical Center Duarte California

4. Department of PediatricsCity of Hope Medical Center Duarte California

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25567

Reference6 articles.

1. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia